1 / 14

Role of Intrathecal Polyanalgesia- Its Cost Impact and Role in Recapturing Pain Control

Role of Intrathecal Polyanalgesia- Its Cost Impact and Role in Recapturing Pain Control. Dr. Krishna Kumar , M.B., M.S., F.R.C.S. (C), F.A.C.S. Syed Rizvi Sharon Bishop BNurs ., MHlthSci. Objective. Practice is changing: increasing use of polyanalgesia

clyde
Télécharger la présentation

Role of Intrathecal Polyanalgesia- Its Cost Impact and Role in Recapturing Pain Control

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Role of Intrathecal Polyanalgesia- Its Cost Impact and Role in Recapturing Pain Control Dr. Krishna Kumar, M.B., M.S., F.R.C.S. (C), F.A.C.S. Syed Rizvi Sharon Bishop BNurs., MHlthSci.

  2. Objective • Practice is changing: increasing use of polyanalgesia • Which patient groups require monotherapy vs polyanalgesia? • When is the introduction of a second agent indicated? • The cost implication of polyanalgesia and does it pay off with improved pain control?

  3. Study Design • We present a retrospective study of 110 patients receiving IDT for treatment of spasticity and CNMP

  4. IDT Drug Regimens Avg 500 days Avg 79 days Avg 240 days 43% of patients require polyanalgesia

  5. Relationship between IDT & Pain Type

  6. Monotherapy- Morphine # of patients 20 20 16 13 12 10 9 7 Baseline

  7. Dual-admixture dosage escalationeg. Hydromorphone+Bupivacaine Mean dose per day # of patients 9 9 9 8 8 6 Monotherapy In most cases, patients are able to reduce narcotic doses and restore effective pain control

  8. Baseline Prior to initiating IDT patients were reporting high levels of pain

  9. Trends in Polyanalgesia Prescribing trends have changed over time • Patients implanted pre-2004 • Initiated dual-drug admixture at 28.01 months (average) • Avg. Time DiagnosisIDT: 6.23 years COMPARED TO • Patients implanted post-2004 • Initiated dual-drug admixture at 5.38 months (average) • Avg. Time DiagnosisIDT: 4.56 years On average patients implanted post 2004 reported 30% better pain relief at the 5 year mark when compared to those pre 2004.

  10. Subgroup Analysis: Pain Relief Monotherapy

  11. Oral Analgesia: Post IDT • 20 (18%) patients discontinued the usage of oral narcotics • The remainder of patients used low dose oral narcotics daily to manage breakthrough pain: Typical: hydromorphone 4-7 mg BID Morphine IR 10 mg BID

  12. hydromorph

  13. Comparative Costs • At 10 years compared to monotherapy • Dual-drug therapy: 27% higher cost • Triple-drug therapy: 54% higher cost Conventional Pharmacotherapy Triple-drug IDT Dual-drug IDT Single-drug IDT ARIMA (Autoregressive Intermediate Moving Average) model

  14. Conclusion • Over the longterm • IDT monotherapy is effective in 57% of cases • Dual drug admixtures were required in 33% of cases, triple drug admixtures in the remaining 10% • Polyanalgesia escalates the average daily cost (20-200% depending on the drugs used) • Polyanalgesia is effective in restoring decay in pain control • It appears better results are achieved when polyanalgesia is initiated earlier in treatment planning (30% better pain control at 5yrs)

More Related